Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Bre... (on of symptoms as well as improving over...)

Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Breast Cancer

Date:8/4/2009

on of symptoms as well as improving overall survival. Over 192,000 women in the United States are diagnosed with breast cancer each year and breast cancer is the second leading cause of cancer death in women. Although survival after breast cancer treatment is improving, there are still over 40,000 deaths per year due to the disease in the Unites States alone.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements,
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Bionovo Announces Closing of Public Offering of Common Stock
2. Bionovo Describes a New Class of Therapeutic Compounds
3. Bionovo Announces 2007 Financial Results and Highlights
4. Bionovo to Present at the Cambria Capital Investor Meeting
5. John D. Baxter, M.D. Joins Bionovos Board of Directors
6. Bionovo to Present at the Rodman & Renshaw 10th Annual Global Investment Conference
7. Bionovo to Present Recent Findings of BN108, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
8. Willa A. Hsueh, M.D., Joins Bionovos Scientific Advisory Board
9. Bionovo Announces Cost Control Measures Taken
10. Bionovo Announces Presentation at the National Cancer Institute
11. Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovos Scientific Advisory Board

Post Your Comments:

(Date:12/15/2009)... Health Technologies, Inc. (OTC Bulletin Board: VHGI) confirmed ... subsidiary of VHGI) has appointed two key industry ... with bringing the Treasure Gulch and Zero Gold ... Additionally, the company is informing interested shareholders and ... Live Investor Town Hall Meeting so that investors ...

(Date:12/15/2009)... Reportlinker.com announces that a ... in its catalogue: ,, ... - Market Forecasts to 2015, Competitive ... ,, http://www.reportlinker.com/p0168099/The-Future-of-Respiratory-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ... author has released its latest research ...

(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, The ... Market Forecasts to 2015, Competitive Benchmarking, ... ,, http://www.reportlinker.com/p0168100/The-Future-of-Autoimmune-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, ... has released its latest research "The ...

(Date:12/15/2009)... Hosted by the Technology-based Learning SIG of ASTD,s ... best eLearning designs. This year nominees, eleven ... The Venza Group entry, a highly engaging ... was selected as the winner of the "Greater ... the panel of distinguished judges. While announcing ...

(Date:12/15/2009)... Ill. and CHENNAI, India, Dec. 15 /PRNewswire-FirstCall/ ... ), the world leader in generic injectable ... (BSE: 524372, NSE: ORCHIDCHEM), a leading Indian ... beta-lactam antibiotics manufacturers globally, today announced an ... injectable finished-dosage form pharmaceuticals business for approximately ...

[0] VHGI: VHGI Gold Taps Key Mining Professionals to Assist With Development Plan for $50,000,000 Potential Reserves at Treasure Gulch Gold Mine; Investor Town Hall Meeting to be Scheduled [0] Reportlinker Adds The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] The Venza Group Received Top Honors at the American Society of Training & Development (ASTD) eLearning Excellence Awards Ceremony Held on December 10, 2009 [0] Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business

... Group on Health and Pharmacy Outcomes Specialists collaborate to produce ... CHICAGO, Dec. 8 The Midwest Business Group on Health ... the second annual Pharmacy Benefits Academy (PBA) to be held ... A collaboration between MBGH and POS, the Academy is part ...

... , , MONDAY, Dec. 8 (HealthDay News) -- An international ... 40,000 people has identified 11 more regions that govern ... triglycerides. , "These locations point us to previously unsuspected ... Dr. Sekar Kathiresan, director of preventive cardiology at Massachusetts ...

... INDIANAPOLIS, Dec. 8 Amylin,Pharmaceuticals, Inc. (Nasdaq: ... LLY ),today announced that the U.S. Food and ... regulatory application for use of BYETTA(R) (exenatide),injection as stand-alone ... not achieving acceptable blood sugar control. It is likely ...

... earns regional designation , , ... the nation,s largest effort to recognize physicians for delivering ... BTE Incentive and Reward Program Endorsement. Aetna ... for meeting performance and recognition standards and principles for ...

... its acclaimed debut in 2007,MyHealthArchive revolutionized every aspect ... bringing the process into the digital age. Today,s,release ... allowing,subscribers to take charge of their health and ... their own centralized control and energizing their health,and ...

... a leading global manufacturer and marketer of nutritional supplements, today announced preliminary unaudited net sales results for the month of November ... by segment are as follows: , , , , ... NET SALES, ... ...

Other Medicine News:Health News:Pharmacy Benefits Academy Set for 2009 2 Health News:Pharmacy Benefits Academy Set for 2009 3 Health News:11 New Cholesterol Genes Identified 2 Health News:11 New Cholesterol Genes Identified 3 Health News:Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission 2 Health News:Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission 3 Health News:Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission 4 Health News:Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission 5 Health News:Health Plans Achieve Bridges to Excellence Physician Incentive and Reward Program Endorsement 2 Health News:Health Plans Achieve Bridges to Excellence Physician Incentive and Reward Program Endorsement 3 Health News:MyHealthArchive.com's New Features -- A Quantum Leap in Using Health Information to Promote Your Health 2 Health News:MyHealthArchive.com's New Features -- A Quantum Leap in Using Health Information to Promote Your Health 3 Health News:MyHealthArchive.com's New Features -- A Quantum Leap in Using Health Information to Promote Your Health 4 Health News:NBTY Announces Preliminary Unaudited Net Sales Results for November 2008 2 Health News:NBTY Announces Preliminary Unaudited Net Sales Results for November 2008 3 Health News:NBTY Announces Preliminary Unaudited Net Sales Results for November 2008 4

Pharmacy Benefits Academy Set for 2009 11 New Cholesterol Genes Identified Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission Health Plans Achieve Bridges to Excellence Physician Incentive and Reward Program Endorsement MyHealthArchive.com's New Features -- A Quantum Leap in Using Health Information to Promote Your Health NBTY Announces Preliminary Unaudited Net Sales Results for November 2008

(Date:12/15/2009)... CITY, Dec. 15 Dynatronics ... signed a preferred vendor agreement to provide therapy ... Inc. (PTP), a nationwide network of physical, occupational ... be working with Preferred Therapy Providers," said Larry ... marketing at Dynatronics. "Their vast network of 1,100 ...

(Date:12/15/2009)... Dec. 15 ,, Reportlinker.com announces ... available in its catalogue: ,, Hepatitis ... Forecasts to 2015 ,, http://www.reportlinker.com/p0167309/Hepatitis-B-Vaccines---Pipeline-Analysis-and-Market-Forecasts-to-2015.html ... Analysis and Market Forecasts to 2015 ,, ... analysis specialist,s new report, "Hepatitis B Vaccines ...

(Date:12/15/2009)... NEW YORK, Dec. 15 Reportlinker.com ... is available in its catalogue: ,, ... http://www.reportlinker.com/p0168539/Boehringer-Ingelheim-GmbH-PharmaVitae-Profile.html ,, Introduction ... forecast performance for Boehringer Ingelheim in the ... strategy, portfolio and pipeline analysis and assessment ...

Breaking Medicine Technology:Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc. 2 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 2 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 3 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 4 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 5 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 6 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 7 Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2 Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3 Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4 Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5 Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6 Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7 John Hancock Announces Enhancements to Group Long Term Care 28LTC 29 Insurance Products and Discount Program 49216 1 John Hancock Announces Enhancements to Group Long Term Care 28LTC 29 Insurance Products and Discount Program 49216 2 John Hancock Announces Enhancements to Group Long Term Care 28LTC 29 Insurance Products and Discount Program 49216 3 John Hancock Announces Enhancements to Group Long Term Care 28LTC 29 Insurance Products and Discount Program 49216 4 Accelerated Development of New Treatment for Multi Drug Resistant Tuberculosis 3A TB Alliance and Tibotec Announce Unique Partnership to Develop TMC20 49213 1 Accelerated Development of New Treatment for Multi Drug Resistant Tuberculosis 3A TB Alliance and Tibotec Announce Unique Partnership to Develop TMC20 49213 2 Accelerated Development of New Treatment for Multi Drug Resistant Tuberculosis 3A TB Alliance and Tibotec Announce Unique Partnership to Develop TMC20 49213 3 New Study Finds 1 in 4 Multiple Sclerosis Patients With High Out of Pocket Costs Not Filling Prescriptions 49210 1 New Study Finds 1 in 4 Multiple Sclerosis Patients With High Out of Pocket Costs Not Filling Prescriptions 49210 2

[0] Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc.[0] Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 [0] Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile

... fMRI Study Completed and Reported Today ... Higher Repeat Dose Study Completed, HAMBURG, Germany and ... EVT) is pleased to announce the,preliminary findings of a ... subtype selective NMDA receptor antagonist, EVT,101. The study was ...

... Study Highlights Growing Therapeutic Value of Cord Blood ... Stems cells derived,from umbilical cord blood are showing ... from a new preclinical study,published in the March ... by researchers from the University of South Florida ...

Other Medicine Technology:Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks 2 Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks 3 Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimer's Disease 2 Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimer's Disease 3 Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimer's Disease 4 Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimer's Disease 5

Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimer's Disease

... presents the i.Series refrigerator ... solutions for the blood ... features than ever before, ... are at the forefront ...

... the i.Series refrigerator iB120, ... for the blood bank. ... than ever before, i.Series ... at the forefront of ...

... precise requirements of blood banking and ... Equipment meets American Association of Blood ... (ANRC) and U.S. Food & Drug ... and platelet incubators feature alarm systems ...

The TBR-360-1-GD is a large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standar...

Medicine Products:

i.Series iB256 Blood Bank Refrigerator i.Series iB120 Blood Bank Refrigerator Blood Bank Refrigerator 3866/3868 Blood Storage Refrigerator TBR-360-1-GD

Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Bre...(on of symptoms as well as improving over...),Health